Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.6 USD | +0.58% | -0.35% | -3.23% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.22% | 184B | |
-1.81% | 107B | |
-4.31% | 67.78B | |
+0.39% | 50.66B | |
+12.38% | 47.64B | |
+4.60% | 41.12B | |
+1.08% | 26.3B | |
+2.38% | 26.04B | |
+15.06% | 25.4B | |
-1.96% | 24.71B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating